Large-scale testing (Phase 3)Study completedNCT00250354
What this trial is testing
The Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
Who this might be right for
Conduct DisorderOppositional Defiant DisorderDisruptive Behavior Disorder
Janssen Pharmaceutica N.V., Belgium 110